Bionxt Solutions Inc (BNXTF)

$0.71 -0.04 (-5.23%)
Market Cap 86.38M
Revenue (ttm) 20,000.00
Net Income (ttm) -3.88M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -19,400.00%
Debt to Equity Ratio -0.35
Volume 4,000
Avg Vol 3,632
Day's Range N/A - N/A
Shares Out 115.76M
Stochastic %K 73%
Beta 0.78
Analysts Strong Buy
Price Target $2.00

Company Profile

BioNxt Solutions Inc. engages in research, development, manufacture, and sale of next generation drug formulations and delivery systems in Austria, Germany, and Switzerland. The company provides BNT23001for the treatment of multiple sclerosis; BNT23002 for the treatment of myasthenia gravis; BNT24002, a sublingual thin film for the treatment of lupus nephritis; BNT24003 for the treatment of rheumatoid arthritis; BNT24004 for longevity and anti-aging; and BNT24004 for the treatment of semaglutide...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Address:
1928 Linden Road, Vancouver, Canada
MakingDreamsReality
MakingDreamsReality Jul. 17 at 12:23 PM
PM mOOvers 👀 $LGVN - Longeveron® Announces U.S. FDA Grants Fast Track Designation for Lomecel-B™ for the Treatment of Mild Alzheimer's Disease $GDTC - CytoMed Therapeutics Acquires Cord Blood Banking Licence and Assets to Entrench Its Strategy in Allogeneic, Off-the-shelf Donor-derived Gamma Delta (γδ) T Cells Technology for Solid and Liquid Cancers $ADTX -Aditxt And Evofem Amend Merger Agreement, Aiming For September 30 Closure; Evofem Acquires FDA-Approved SOLOSEC $WD -Reported Earlier, Walker & Dunlop Arranges $167M Sale Of Millennium PQ, Second Largest Single-Asset Sale In California For 2024 $BNXTF -BioNxt Signs Statement of Work with International Contract Research, Development, And Manufacturing Organization for Cladribine ODF Development
0 · Reply
NetworkNewsWire
NetworkNewsWire Mar. 14 at 7:20 PM
BioMedNewsBreaks – $BNXT.CN $BNXTF $BXT.F Announces Highly Promising Results from ODF Cladribine PK Study https://ibn.fm/eXd9A
0 · Reply
Stock_Titan
Stock_Titan Dec. 22 at 12:52 AM
$BNXTF BioNxt Solutions Announces Completion of Cladribine ODF Toxicity Study and Financing
0 · Reply
Stock_Titan
Stock_Titan Nov. 25 at 1:07 AM
$BNXTF Bionxt Solutions Announces Convertible Debenture and Interest Settlement Article Available on StockTitan Website.
0 · Reply
Stock_Titan
Stock_Titan Nov. 20 at 8:06 AM
$BNXTF BioNxt Accelerates Cladribine ODF Clinical and Commercialization Strategy for Multiple Sclerosis Treament Article Available on StockTitan Website.
0 · Reply
Stock_Titan
Stock_Titan Nov. 15 at 8:06 AM
$BNXTF BioNxt Reports on New Cladrabine ODF Product Development and Commercialization Program Article Available on StockTitan Website.
0 · Reply
Stock_Titan
Stock_Titan Nov. 13 at 8:06 AM
$BNXTF BioNxt Signs Definitive Agreement For 100% Acquisition of IP And Co-Development of Cladribine ODF Drug Reformulation for The Treatment of Multiple Sclerosis https://www.stocktitan.net/news/BNXTF/bio-nxt-signs-definitive-agreement-for-100-acquisition-of-ip-and-co-xu5udv2qrrt3.html
0 · Reply
Stock_Titan
Stock_Titan Nov. 6 at 8:06 AM
$BNXTF BioNxt Solutions Reports on Barcelona CPHI Conference https://www.stocktitan.net/news/BNXTF/bio-nxt-solutions-reports-on-barcelona-cphi-sl5271u3t2v7.html
0 · Reply
Stock_Titan
Stock_Titan Oct. 27 at 10:21 PM
$BNXTF BioNxt Solutions Announces Closing of Third and Final Tranche of Non-Brokered Private Placement https://www.stocktitan.net/news/BNXTF/bio-nxt-solutions-announces-closing-of-third-and-final-tranche-of-n6xnfj4jquhl.html
0 · Reply
Stock_Titan
Stock_Titan Oct. 3 at 8:31 PM
$BNXTF BioNxt Solutions Announces Change of Directors https://www.stocktitan.net/news/BNXTF/bio-nxt-solutions-announces-change-of-a3rodkjnyino.html
0 · Reply
Latest News on BNXTF
No data available.
MakingDreamsReality
MakingDreamsReality Jul. 17 at 12:23 PM
PM mOOvers 👀 $LGVN - Longeveron® Announces U.S. FDA Grants Fast Track Designation for Lomecel-B™ for the Treatment of Mild Alzheimer's Disease $GDTC - CytoMed Therapeutics Acquires Cord Blood Banking Licence and Assets to Entrench Its Strategy in Allogeneic, Off-the-shelf Donor-derived Gamma Delta (γδ) T Cells Technology for Solid and Liquid Cancers $ADTX -Aditxt And Evofem Amend Merger Agreement, Aiming For September 30 Closure; Evofem Acquires FDA-Approved SOLOSEC $WD -Reported Earlier, Walker & Dunlop Arranges $167M Sale Of Millennium PQ, Second Largest Single-Asset Sale In California For 2024 $BNXTF -BioNxt Signs Statement of Work with International Contract Research, Development, And Manufacturing Organization for Cladribine ODF Development
0 · Reply
NetworkNewsWire
NetworkNewsWire Mar. 14 at 7:20 PM
BioMedNewsBreaks – $BNXT.CN $BNXTF $BXT.F Announces Highly Promising Results from ODF Cladribine PK Study https://ibn.fm/eXd9A
0 · Reply
Stock_Titan
Stock_Titan Dec. 22 at 12:52 AM
$BNXTF BioNxt Solutions Announces Completion of Cladribine ODF Toxicity Study and Financing
0 · Reply
Stock_Titan
Stock_Titan Nov. 25 at 1:07 AM
$BNXTF Bionxt Solutions Announces Convertible Debenture and Interest Settlement Article Available on StockTitan Website.
0 · Reply
Stock_Titan
Stock_Titan Nov. 20 at 8:06 AM
$BNXTF BioNxt Accelerates Cladribine ODF Clinical and Commercialization Strategy for Multiple Sclerosis Treament Article Available on StockTitan Website.
0 · Reply
Stock_Titan
Stock_Titan Nov. 15 at 8:06 AM
$BNXTF BioNxt Reports on New Cladrabine ODF Product Development and Commercialization Program Article Available on StockTitan Website.
0 · Reply
Stock_Titan
Stock_Titan Nov. 13 at 8:06 AM
$BNXTF BioNxt Signs Definitive Agreement For 100% Acquisition of IP And Co-Development of Cladribine ODF Drug Reformulation for The Treatment of Multiple Sclerosis https://www.stocktitan.net/news/BNXTF/bio-nxt-signs-definitive-agreement-for-100-acquisition-of-ip-and-co-xu5udv2qrrt3.html
0 · Reply
Stock_Titan
Stock_Titan Nov. 6 at 8:06 AM
$BNXTF BioNxt Solutions Reports on Barcelona CPHI Conference https://www.stocktitan.net/news/BNXTF/bio-nxt-solutions-reports-on-barcelona-cphi-sl5271u3t2v7.html
0 · Reply
Stock_Titan
Stock_Titan Oct. 27 at 10:21 PM
$BNXTF BioNxt Solutions Announces Closing of Third and Final Tranche of Non-Brokered Private Placement https://www.stocktitan.net/news/BNXTF/bio-nxt-solutions-announces-closing-of-third-and-final-tranche-of-n6xnfj4jquhl.html
0 · Reply
Stock_Titan
Stock_Titan Oct. 3 at 8:31 PM
$BNXTF BioNxt Solutions Announces Change of Directors https://www.stocktitan.net/news/BNXTF/bio-nxt-solutions-announces-change-of-a3rodkjnyino.html
0 · Reply
Stock_Titan
Stock_Titan Sep. 28 at 11:31 PM
$BNXTF Bionxt Solutions Announces Closing of Second Tranche of Non-Brokered Private Placement https://www.stocktitan.net/news/BNXTF/bionxt-solutions-announces-closing-of-second-tranche-of-non-brokered-g557kq4ji3cu.html
0 · Reply
Stock_Titan
Stock_Titan Aug. 5 at 12:12 AM
$BNXTF BioNxt Solutions Announces Non-Brokered Private Placement https://www.stocktitan.net/news/BNXTF/bio-nxt-solutions-announces-non-brokered-private-chyno44ekm63.html
0 · Reply
Stock_Titan
Stock_Titan Aug. 2 at 7:00 AM
$BNXTF BioNxt Signs LOI for Acquisition of IP and Co-Development of ODF Drug Reformulation for Neurodegenerative Disease https://www.stocktitan.net/news/BNXTF/bio-nxt-signs-loi-for-acquisition-of-ip-and-co-development-of-odf-1nfhv4lwb9ak.html
0 · Reply
fruttifresh76
fruttifresh76 Aug. 1 at 6:32 PM
$BNXTF long here for Sure!
0 · Reply
Billno
Billno Jul. 3 at 6:27 PM
$BNXTF Well now !? What da heck happened here ?
0 · Reply